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2013, accepted Jancomplete stent apposition (ISA) is characterized by the lack of contact of at least 1 stent strut with the vessel wall in
a segment not overlying a side branch; it is more commonly found in drug-eluting stents than bare-metal stents. The
accurate diagnosis of ISA, initially only possible with intravascular ultrasound, can currently be performed with higher
accuracy by optical coherence tomography, which also enables strut-level assessment due to its higher axial
resolution. Different circumstances related both to the index procedure and to vascular healing might inﬂuence ISA
occurrence. Although several histopathology and clinical studies linked ISA to stent thrombosis, potential selection
bias precluded deﬁnitive conclusions. Initial studies usually performed single time point assessments comparing
overall ISA percentage and magnitude in different groups (i.e., stent type), thus hampering a comprehensive
understanding of its relationship with vascular healing. Serial intravascular imaging studies that evaluated vascular
response heterogeneity recently helped ﬁll this gap. Some particular clinical scenarios such as acute coronary
syndromes, bifurcations, tapered vessels, overlapping stents, and chronic total occlusions might predispose to ISA.
Interventional cardiologists should be committed to optimal stent choices and techniques of implantation and use
intravascular imaging guidance when appropriate to aim at minimizing acute ISA. In addition, the active search
for new stent platforms that could accommodate vessel remodeling over time (i.e., self-expandable stents) and
for new polymers and/or eluting drugs that could induce less inﬂammation (hence, less positive remodeling)
could ultimately reduce the occurrence of ISA and its potentially harmful consequences. (J Am Coll Cardiol
2014;63:1355–67) ª 2014 by the American College of Cardiology FoundationIncomplete stent apposition (ISA), also described as stent
malapposition, is a morphological characteristic deﬁned by
the lack of contact between at least 1 stent strut and the
underlying intimal surface of the vessel wall in a segment not
overlying a side branch. Due to the lack of sufﬁcient resolu-
tion and the inability of providing cross-sectional images,
angiography does not allow the diagnosis of ISA, whereas
high-resolution intravascular imaging modalities, such as
intravascular ultrasound (IVUS) (axial resolution of approx-
imately 150 mm) and optical coherence tomography (OCT)
(axial resolution of approximately 10 to 15 mm) do allow
diagnosis (1). According to the time that ISA is diagnosed
relative to the index procedure, ISA is labeled as acute
(i.e., diagnosed post-procedure), persistent (i.e., diagnosed
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uary 7, 2014.acquired (i.e., not present post-procedure, but identiﬁed at
follow-up assessment). In the absence of baseline intravas-
cular imaging assessment, it is described simply as late ISA
(2,3). Several factors are responsible for this pathological
phenomenon and its different presentations, as follows:
1) inadequate stent implantationdin this setting, there are
basically 2 possibilities: a) marked mismatch between stent
size selection and luminal dimensions (i.e., stent diameter
smaller than reference lumen diameter), a situation in which,
regardless of optimal stent expansion, ISA will occur (4);
or b) stent underexpansion despite an adequate stent–artery
ratio due to several different factors, such as inadequate
pressure of implantation and/or plaque-related factors
(Fig 1); 2) chronic stent recoil (5); 3) thrombus dissolution
after primary percutaneous coronary intervention (PCI) (6);
4) positive vessel remodeling (6–11); and 5) inadequate
(i.e., insufﬁcient and/or delayed) neointimal hyperplasia
(12–15).
Incomplete Stent Apposition and Potential
Relationship With Adverse Clinical Outcomes
A clear relationship between ISA and adverse cardiovascular
events is still controversial. Although some studies have
Figure 1 ISA in Vessels W
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Abbreviations
and Acronyms
BMS = bare-metal stent(s)
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
ISA = incomplete stent
apposition
IVUS = intravascular
ultrasound
OCT = optical coherence
tomography
OLP = overlapping
PCI = percutaneous coronary
intervention
PES = paclitaxel-eluting
stent(s)
ST = stent thrombosis
SES = sirolimus-eluting
stent(s)
ZES = zotarolimus-eluting
stent(s)
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1356failed to demonstrate such con-
nections (7,16–18), others have
done so (12,19–24) (Table 1).
Lee et al. (25) demonstrated that
among 30 patients with very late
stent thrombosis (ST), 73.9% of
the drug-eluting stent (DES) group
exhibited ISA (among whom
64.7% had late acquired ISA),
whereas none of the bare-metal
stent (BMS) group had ISA.
Although the results showed a
higher incidence of ISA in pa-
tients with DESs compared with
BMSs, conﬁrming data from
previous reports (20), they also
highlighted that ISA is not an
isolated factor responsible for
DES thrombosis (i.e., 26.1% of
DES patients had stent throm-
bosis without evident ISA) (25).
Guagliumi et al. (26) demon-
strated by combined IVUS andOCT assessments that the presence and magnitude (i.e.,
area and distance) of ISA were signiﬁcantly higher in pa-
tients with DES thrombosis compared with those without
DES thrombosis. In addition, these investigators implicated
1 mechanism that led to ISA (i.e., positive remodeling) and
another mechanism that could be a consequence of ISA
(i.e., uncovered stent struts) as independent predictors of
DES thrombosis (Fig. 2). Eosinophilic-rich inﬂammatory
inﬁltrates associated with positive remodeling were alsoith Similar Dimensions
circle) with 3-mm diameter is depicted.
nd to a representation of a 2.5-mm stent
ing 2.7 mm. In this situation, although the
ded, incomplete stent apposition (ISA)
tent–vessel mismatch. (C) Conversely, a
igh pressure is seen, in which the horizontal
vertical diameter is only 2.5 mm as the
yellow with red dots) that impair proper
in some regions of the stent. Figure is bydemonstrated (27). Alfonso et al. (27) also identiﬁed ISA
in patients with ST using IVUS and OCT (ISA was iden-
tiﬁed in 40% and 47% of patients, respectively). Kang et al.
(28) performed OCT imaging in 33 patients with very late
ST and found that in the DES group, 52% and 64% had
ISA and thrombi, respectively, whereas no patients pre-
sented with ISA in the BMS group. ISA was also more
frequently found in 124 patients with very late deﬁnite DES
versus BMS thrombosis (52% vs. 16%, respectively,
p ¼ 0.005) in a multicenter registry. Notably, greater ISA
area was also demonstrated in the DES group compared
with the BMS group. Moreover, among the DES group, a
higher prevalence of ISA was identiﬁed in sirolimus-eluting
stents (SES) compared with paclitaxel-eluting stents (PES)
(58% vs. 37%, respectively, p ¼ 0.02) (29). More recently,
higher rates of ISA were revealed in 34 patients with DES
(56%) and BMS (11%) thrombosis in Italy (30). Although
extremely insightful, cautious interpretation of these results
is crucial due to potential selection bias.
Understanding the underlying mechanisms involved in
ISA is of paramount importance to the interventional cardi-
ologist because it enables the identiﬁcation of which features
are potentially modiﬁable and which resources should be
utilized during the index intervention to optimize implanta-
tion quality andminimize the likelihood of having ISA and its
potentially harmful consequences (31–33). Although physi-
ological vascular healing after stent implantation leads to
progressive reduction of ISA over time (12–14,34,35), recent
serial OCT assessments elucidated this complex mechanism
more clearly, showing that the greater the acute ISA (i.e., after
the index procedure), the higher the possibility of its persis-
tence at follow-up (14,15). Furthermore, these studies
demonstrated that acute ISA affects the overall vascular
response negatively, ultimately leading to delayed stent strut
coverage (12–15) and even to ST (12). The comprehension of
this complex scenario, moreover, is key for investigators and
biomedical engineers so that they can actively search for
constant improvements in mechanical (i.e., stent platforms)
(36) and biological (i.e., antirestenotic drugs, polymers) (37)
components of coronary artery scaffolds.
Histopathology Investigations
Histopathology studies have been instrumental in enabling a
better understanding of mechanisms that lead to ISA. The
pivotal demonstration by Virmani et al. (37) that Cypher
(Cordis, Johnson & Johnson, New Brunswick, New Jersey)
SES thrombosis was linked to hypersensitivity reactions and
to a complex proinﬂammatory milieu raised the initial
concerns regarding the safety issues of DESs (37). The in-
vestigators identiﬁed the presence of ISA with thick layers
of ﬁbrin thrombus separating stent struts from the vessel
wall. In a larger series of patients, Joner et al. (38) ratiﬁed
the complexity of the multifactorial scenario (i.e., procedural
and clinical related features) associated with DES failure,
describing the presence of ISA coupled with delayed arterial
Table 1 Impact of ISA on Cardiovascular Events
First Author (Ref. #) Design N
Clinical
Presentation Type of Stent
Assessed
by
Follow-Up
(Months) Assessment of Malapposition
Positive Association Between
ISA and Cardiovascular Events
Guagliumi et al. (22) PP, SC 21 Stable/ACS ZES OCT 6 Malapposed struts per stent: 2.0  4.2% (OLP),
3.8  7.1% (non-OLP)
No
Kubo et al. (23) PP, SC 45 Stable/ACS SES OCT 9 Malapposed struts per stent: 0.2  1.2% (stable),
4.0  6.7% (ACS)
No
Guagliumi et al. (24) PP, SC 77 Stable/ACS SES/PES/ZES/BMS OCT 6 Malapposed struts per stent: 2.9  7.0% (SES; OLP),
1.9  4.2% (SES; non-OLP),
malapposed struts per stent: 5.5  15.6%
(PES; OLP), 0.7  2.1% (PES; non-OLP),
malapposed struts per stent: 0.1  0.2%
(ZES; OLP), 0.1  0.1% (ZES; non-OLP),
malapposed struts per stent: 0.1  0.1%
(BMS; OLP), 0.2  0.9% (BMS; non-OLP)
No
Guagliumi et al. (22) PP, SC 42 Stable/ACS EES CoCr/EES PtCr OCT 6 Malapposed struts per stent: 0.5%, malapposition
area 0.02 mm2 (EES CoCr), malapposed struts
per stent: 0.0%, malapposition area 0.01 mm2
(EES CoCr)
No
Hong et al. (16) RP, SC 557 Stable/ACS SES/PES IVUS 6 LSM CSA: 3.0  1.9 mm2 (SES), 3.2  1.9 mm2
(PES) (LSM occurred in 12.1% of lesions)
No
Steinberg et al. (17) PP, MC 1,580 Stable/ACS PES/BMS IVUS 9 Late-acquired ISA was identiﬁed in 2.7% of BMS,
3.1% of PES-SR, and 15.4% of PES-MR
No
Tanabe et al. (18) PP, MC 469 Stable/ACS PES/BMS IVUS 6 Mean ISA area: 3.6  1.2 mm2 (PES-SR),
2.1  1.4 mm2 (PES-MR), 3.0  2.1 mm2 (BMS)
No
Cook et al. (19) PP, MC 194 Stable/ACS SES/PES IVUS 8 Max ISA CSA: 4.5  5.0 mm2 (SES), 5.0  5.1 mm2
(PES), total ISA length: 2.3  1.4 mm (SES),
1.0  0.9 mm (PES)
Yes (the presence of ISA after
DES implantation was associated
with a higher rate of MI and VLST)
Cook et al. (21) PP, SC 188 Stable/ACS SES/PES IVUS 8 Max ISA CSA: 8.3  7.5 mm2 (VLST), 4.0  3.8 mm2
(control), max ISA length: 6.3  6.3 mm2 (VLST),
1.5  1.0 mm2 (control)
Yes (ISA is highly prevalent in patients
with VLST after DES implantation)
ACS ¼ acute coronary syndrome(s); BMS¼ bare-metal stent(s); CoCr ¼ cobalt-chromium; CSA ¼ cross-sectional area; EES¼ everolimus-eluting stent(s); ISA¼ incomplete stent apposition; IVUS¼ intravascular ultrasound; LSM ¼ late stent malapposition; MACE¼major adverse
cardiac event(s); MC ¼ multicenter; MI ¼ myocardial infarction; MR ¼ moderate-release; OCT ¼ optical coherence tomography; OLP ¼ overlapping; PCI ¼ percutaneous coronary intervention; PES ¼ paclitaxel-eluting stent; PP ¼ prospective; PtCr ¼ platinum-chromium;
RP ¼ retrospective; SC ¼ single center; SES ¼ sirolimus-eluting stent(s); SR ¼ slow-release; VLST ¼ very late stent thrombosis; ZES ¼ zotarolimus-eluting stent(s).
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Figure 2 Late ISA, Thrombosis, and Neoatherosclerosis
This 60-year-old patient had multiple drug-eluting stents implanted in overlapping fashion in the right coronary artery (RCA) 6 years before the current hospitalization due to
non–ST-segment elevation myocardial infarction. (A) Angiography demonstrates “haziness” in the mid-RCA (white arrow). The white dashed lines in the longitudinal optical
coherence tomographic (OCT) image (bottom) correspond to the respective locations of the cross sections identiﬁed by the same letter. (B) A normal pattern of thin neointimal
proliferation is depicted without incomplete stent apposition (ISA) or uncovered struts. (C, D, E). However, ISA with some attached thrombus is depicted (white arrows). (F) A
huge intraluminal thrombus burden is depicted (white arrow), whereas in (G) another normal pattern (thin, bright tissue covering the struts) of vascular response is depicted.
(H) A transition to an abnormal pattern of stent coverage is shown as low-signal intensity tissue, identiﬁed as peri-struts (i.e., acellular material, such as ﬁbrin or proteoglycan).
(I) Although normal tissue covers the struts from 1 to 7 o’clock, the white dashed square in J demonstrates lipidic tissue (marked light attenuation with poorly deﬁned borders,
white asterisk) covering the stent (i.e., neoatherosclerosis), which almost “hides” the stent struts (white arrows), and a thin cap overlying the lipid plaque (white arrowheads).
This case has important teaching points, as follows: 1) In a long stented segment, there is minimal ISA, but it is linked to stent thrombosis; therefore, it is important to perform
lesion-level assessments rather than display only an overall percentage of the ISA and the assessment of ISA clusters in clinical trials; 2) Although a clear relationship between
the acellular tissue peri-strut (i.e., potentially secondary to inﬂammation drug and/or polymer toxicity) identiﬁed in H and the ISA (i.e., eventually secondary to positive
remodeling due to drug and/or polymer toxicity) cannot be clearly derived from this case, one can speculate that these pathological phenomena could be linked by a proin-
ﬂammatory milieu (35); and 3) Similar rationale of item 2 can be derived from the lipidic neointimal tissue covered by thin ﬁbrous cap identiﬁed more proximally (I and J).
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1358healing and the presence of ﬁbrin surrounding the stent
struts as 1 of the mechanisms associated with ST (35)
(Fig. 2). More recently, Cook et al. (39) correlated the
histopathology of thrombus aspirates with IVUS ﬁndings
in patients with very late DES thrombosis. Interestingly,
they were able to establish a correlation between the am-
ount of eosinophil inﬁltrates with the extent of positive
vessel remodeling, suggesting hypersensitivity reactions of
all 3 layers of the vessel wall in patients with ISA; in pa-
tients without positive remodeling, however, only a few or
no eosinophils were detected. Despite the outstanding
contribution of histopathology research toward a better
comprehension of the mechanisms that lead to ISA and its
potential consequences, the data presented by these studies
should be carefully interpreted because they represent a
highly selected population (i.e., patients who had a DES
implanted and died). Therefore, although ISA is suggestedas 1 of the potential mechanisms linked with adverse car-
diovascular events in these studies, a linear cause and effect
relationship cannot be derived from these ﬁndings.
Another signiﬁcant role played by histopathology in this
scenario is the validation of intravascular imaging ﬁndings,
which is of utmost importance because they enable accurate
in vivo qualitative (rather than merely quantitative) assess-
ments of vascular responses in a prospective fashion, which
could ultimately facilitate the understanding of the patho-
physiology of ISA. The feasibility and accuracy of tissue
characterization utilizing OCT has been previously demon-
strated (40–42). This could be particularly important to help
elucidate, for example, the underlying mechanisms that lead
to ISA in different scaffolds (Fig. 3) (43). Radu et al. (44)
suggested the term “pseudoapposed” to deﬁne stent struts
that were “apposed” to low-signal intensity regions, which
were likely composed of acellular material such as ﬁbrin or
JACC Vol. 63, No. 14, 2014 Attizzani et al.
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1359proteoglycan, and similar to what has been described by
histopathology (38). Further investigations are required to
assess the relevance of these ﬁndings.
Fundamental Differences Between
IVUS and OCT in ISA Interpretation
Due to their high resolution, intravascular imaging modal-
ities are essential to properly diagnose ISA in vivo. Although
a complete description of IVUS and OCT imaging is beyond
the scope of this paper, it is important to be cognizant of the
fundamental differences and potential additive values of these
imaging systems in the diagnosis of ISA, hence, facilitating
data interpretation.
IVUS is a sound-based imaging system with an axial
resolution of approximately 150 mm and a penetration of 4
to 8 mm. It enables detailed assessment of vessel size because
the external elastic membrane is clearly visualized, therefore
allowing accurate quantiﬁcation of positive vascular remod-
eling (45,46). The diagnosis of ISA by IVUS is determined
by the presence of blood speckle (or also by color Doppler
imaging in the case of lower frequency IVUS) behind the
stent struts not overlying a side branch. Data are provided
in cross-sectional (i.e., area of ISA) and longitudinal (i.e.,
volume of ISA) levels (6). Conversely, OCT is a near-
infrared, light-based system with an approximately 10-fold
higher resolution (approximately 10- to 15-mm axial reso-
lution) compared with IVUS, but with less tissue penetra-
tion (1 to 3 mm). This lack of deep tissue penetration
precludes accurate quantiﬁcation of positive vessel remod-
eling, whereas the blood-free environment obtained during
OCT image acquisition, coupled with its higher axial reso-
lution, provides a sharper delineation of the stent–lumen
interface compared with IVUS, thus allowing easier image
interpretation (1,47) (Fig. 4). Several authors demonstrated
that OCT is superior to IVUS in detecting ISA, including
in the left main coronary artery (1,12,27,48). Another
important piece of information added by OCT on top of
cross-sectional and longitudinal levels of assessment is the
strut-level analysis, which enables the diagnosis and quan-
tiﬁcation of ISA in each individual strut. It is also important
to highlight that the initial diagnosis of ISA by OCT,
including that performed in the catheterization laboratory in
our daily practice, is qualitative, whereas the ﬁnal determi-
nation of whether or not 1 strut exhibits ISA is quantitative
(i.e., considering blooming, strut, and polymer thicknesses)
(Fig. 5) (49,50). Taken together, these characteristics
indicate that IVUS and OCT complement each other in the
diagnosis and elucidation of ISA mechanisms (26,27).
Study Designs and Endpoints
Several studies have evaluated ISA by single time point (i.e.,
follow-up) assessments (51–55). Although the information
provided by these studies is extremely valuable in the deter-
mination of ISA rates using different stents in vivo, it isimpossible to completely elucidate this morphological feature
in a single “snapshot.” Healing after stent implantation is a
continuum inﬂuenced by several different factors, related to
both baseline characteristics (i.e., clinical and procedure
related) and to alterations that occur along this complex
biological process (i.e., inﬂammation, delayed healing, and
positive remodeling); therefore, serial intravascular imaging
studies using IVUS and/or OCT (11,12,14,15,35,56) have
helped to ﬁll the gap left by single time point assessments.
Despite the importance of serial invasive imaging assess-
ments to comprehensively characterize the natural history
of ISA, increased costs, coupled with ethical issues of sub-
mitting patients to the inherent risks of repeated invasive
interventions, x-ray exposure, and contrast media injections,
have hampered their more extensive utilization (57,58).
Another consideration is that data presentation across
studies evaluating ISA lacks standardization. The majority
of trials provide overall percentages, areas, and volumes of
ISA associated with the groups (i.e., different stents) being
evaluated (59,60), rather than identifying and quantifying
segments in which the abnormality is present (i.e., lesion-
level assessment) (61), therefore restricting the assessment
of intra- and interindividual heterogeneity of vascular
responses, and consequently, of ISA. Räber et al. (62)
demonstrated that, despite an overall equivalent percentage
of ISA late after SES and PES implantation, signiﬁcant
clustering of ISA was depicted in the former, suggesting
different patterns of vascular responses between the scaffolds
being evaluated. Gutiérrez-Chico et al. (15) described het-
erogeneous morphological healing patterns in patients with
acute ISA using serial OCT imaging assessments. Another
tool to assess whether heterogeneity exists in vascular re-
sponses is the coefﬁcient of variation, which is obtained
by dividing each lesion into subsegments (i.e., dividing
the standard deviation by the mean percentage of ISA)
(35,63–65). These analytical approaches could ultimately
expand our knowledge of assessing pathological vascular
reactions to stents, particularly ISA, and avoiding, for
instance, the “diluting” of the results of clustered ISAs that
may occur in localized segments of certain individuals,
and in the entire population of the study. Whether these
ﬁndings signiﬁcantly affect clinical outcomes remains to be
demonstrated.Incomplete Stent Apposition in
Different Clinical Scenarios
Acute coronary syndromes. Nakazawa et al. (66) used
histopathology to demonstrate that vascular healing was
delayed and ST rates were increased in patients who under-
went DES implantation for myocardial infarction compared
with stable angina; culprit sites in the former had greater
ﬁbrin deposition and inﬂammation, together with less neo-
intimal proliferation. In addition, higher rates of struts
penetrating the necrotic core and greater external elastic
membrane areas were found. Hong et al. (67) showed in vivo
Figure 3 Representative Images of Late Stent Thrombosis in First-Generation SES and ISA in PES
(A) Histological sections from sirolimus-eluting stents (SES). A 40-year-old woman who received 2 SES in the left anterior descending artery (LAD) and right coronary artery (RCA)
17 months ante mortem died suddenly 4 days after surgical removal of a melanoma (wide excision). Antiplatelet therapy (aspirin and clopidogrel) was discontinued 5 days before
the surgery. Histological sections of the SES in the LAD showed total thrombotic occlusion and diffuse inﬂammation (a). Numerous inﬂammatory cells were observed within
the neointimal area (b). Inﬂammatory reaction predominantly consists of T lymphocytes (c) (CD45RO) and eosinophils (d) (Luna stain). Note that the same reaction was
observed in the SES in the RCA (e), and severe inﬂammation resulted in incomplete stent apposition (ISA) of stent struts (f). (B) Histological sections from a PES showing ISA. A
69-year-old man who received a paclitaxel-eluting stent (PES) in a saphenous vein graft died suddenly 3 months after stent placement. Histological sections showed thrombotic
occlusion in the PES (a, b); note the ISA was secondary to severe ﬁbrin deposition (c). A 48-year-old man with a PES implant in the proximal LAD died suddenly at 40 months.
Histological sections showed thrombotic occlusion of the PES (d). Most struts show ISA with ﬁbrin deposition underneath the stent struts (e, f). Thr ¼ thrombus. Adapted and
reprinted with permission from Nakazawa et al. (43).
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1360that BMS implantation during primary PCI was an inde-
pendent predictor of late ISA, but it was not linked to
increased rates of adverse events at 3-year follow-up. In a
serial assessment by IVUS, BMS and PES rates of acute ISA
were equivalent, whereas PES were more frequently associ-
ated with late acquired ISA at follow-up, mostly because
of thrombus dissolution and positive remodeling. The in-
vestigators also found that an area of acute ISA >1.2 mm2
determined resolved ISA from persistent ISA (6). Likewise,
no differences were observed between SESs and BMSsregarding acute ISA rates after primary PCI (38.5% and
33.8%, p ¼ 0.51), whereas late acquired ISA was more often
identiﬁed in SES, mainly secondary to positive vessel
remodeling (84% of the cases) (68). Data obtained from the
HORIZONS-AMI (Harmonizing Outcomes With Revas-
cularization and Stents in AcuteMyocardial Infarction) study
did not link early stent thrombosis with the presence of acute
ISA (69); in addition, the 13-month follow-up of the
HORIZONS-OCT study included 188 stents (PES and
BMS) and showed higher rates of late ISA with PES
Figure 4 ISA by IVUS and OCT
In A-I, an intravascular ultrasound (IVUS) cross-sectional image shows stent struts (red arrows) with ISA (yellow asterisks). The same co-registered region of interest is
demonstrated in an OCT image (A-II), in which one can also identify the stent struts (red arrows) with ISA (yellow asterisks). In B-I, however, the IVUS image does not enable a
clear diagnosis of ISA, whereas in the same co-registered region (B-II) imaged by OCT, the presence of stent struts (red arrow) with ISA (yellow asterisks) is clearly depicted.
The blue lines in the longitudinal views located in the bottom of each cross section demonstrate the region of the pullback from which the cross sections were obtained.
Abbreviations as in Figures 2 and 3.
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1361compared with BMS (70). Gonzalo et al. (71) used OCT
imaging to demonstrate, in vivo, that DESs implanted during
primary PCI compared with stable and/or unstable angina
more often had ISA at 9-month follow-up (75% vs. 25.8%,
respectively, p ¼ 0.001). The investigators also identiﬁed
DES implantation during primary PCI as the only inde-
pendent predictor of ISA (odds ratio: 9.8, 95% conﬁdence
interval: 2.4 to 40.4; p¼ 0.002). Davlouros et al. (72) showed
in a small study that ISA was correlated with a lack of
coverage 6 months after PES implantation for acute coronary
syndromes. Kubo et al. (23) compared unstable versus stable
angina patients who underwent DES implantation andFigure 5 Quantiﬁcation of ISA by OCT
In daily clinical practice, the initial assessment of ISA by OCT is qualitative, as demonstrate
several factors such as polymer and strut thicknesses (different for each stent) and one-h
malapposed distance. ISA quantiﬁcation of some struts are demonstrated by the purple sq
strut (blue arrow), which although seemed to be ISA by qualitative assessment, was actu
whereas another strut was demonstrated to be malapposed (green square, malapposed ddemonstrated signiﬁcantly higher rates of both acute (67%
vs. 32%; p ¼ 0.038) and late ISA (33% vs. 4%, respectively;
p ¼ 0.012) in the former setting; no adverse events were
reported in the 55 patients in this study at 9-month follow-
up. Adrenergic vasoconstriction, which leads to underesti-
mation of the reference vessel size, which then leads to an
equivocal stent choice (i.e., smaller than vessel dimensions), is
another potential cause of ISA after acute myocardial
infarction (73). The European Guidelines on ST-segment
elevation myocardial infarction recommend intracoronary
administration of nitrates for more accurate stent sizing
during primary PCI (74).d in A; however, the accurate determination of ISA is ultimately quantitative, because
alf of the blooming should be taken into account for the determination of the ﬁnal
uares in B, whereas the region highlighted by the white square in C demonstrates a
ally properly apposed (i.e., in contact with the lumen boundary, blue dashed line),
istance calculation on the right side of the ﬁgure). Abbreviations as in Figure 2.
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1362Overlapping stents. In overlapping (OLP) stent regions, a
greater amount of metal and increased concentrations of
eluting drugs or polymers might increase the risk of ﬂow
disruption, inﬂammation, ﬁbrin deposition, and thrombotic
events. Finn et al. (75) performed histopathological evaluation
of OLP stents in animal models and showed that although
both ﬁrst-generation SES and PES promoted delayed arterial
healing and inﬂammation at OLP sites compared with BMS,
PES had greater ﬁbrin deposition and medial cell loss, as well
as a greater external elastic membrane area compared with
both SES and BMS. In concordance, immature neointima
was found by Shinke et al. (76) in OLP PES regions;
furthermore, these investigators used angioscopy to identify
more thrombus in PES compared with BMS OLP regions.
Recently, an in vitro assessment linked BMS deployed in ISA
or OLP fashions with higher thrombogenicity compared with
well-apposed, length-matched controls (1.58-fold, p< 0.001;
and 2.32-fold, p < 0.001). The investigators also demon-
strated that thin struts were less prone to thrombosis
compared with thick-strut stents (77). The concerns raised by
histopathology and in vitro data were ampliﬁed by in vivo
OCT evaluation performed by Tanigawa et al. (78), who
showed signiﬁcantly higher rates of acute ISA in OLP versus
non-OLP regions despite aggressive stent optimization,
and by Guagliumi et al. (24), who demonstrated higher rates
of late ISA inOLP segments of SES and PES compared with
zotarolimus-eluting stents (ZES) and BMS. In the same
study, numerically higher, although not statistically signiﬁ-
cant, rates of ISA were found in OLP compared with
non-OLP PES, whereas no differences were shown in the
SES, ZES, and BMS groups (24). Aoki et al. (79) did not
highlight concerns regarding ISA in OLP PES segments
at 9-month follow-up. Meanwhile, Otake et al. (80) de-
monstrated that despite the vessel size increase after OLP
PES, no signiﬁcant ISA was demonstrated; likewise, no
signiﬁcant ISA was demonstrated in the everolimus-eluting
stent (EES) group in the same retrospective IVUS study at
9-month follow-up. In addition, Dawkins et al. (81) did not
show increased ISA in OLP segments of PES. An interesting
insight in this setting was recently demonstrated by
Guagliumi et al. (22); similar stent platforms and anti-
restenotic drugs (i.e., zotarolimus), but different polymers and
release kinetics, led to different rates of ISA in OLP regions
(i.e., slow-release ZES showed higher rates of ISA compared
with fast-release ZES). Different stent platforms (i.e., cobalt-
chromium vs. platinum-chromium), but same drug-release
kinetics, in EES did not reveal differences in terms of
ISA (82). The importance of the underlying plaque in
the results of OLP stenting was investigated by Tahara et al.
(83), who demonstrated that increased rates of ISA and
uncovered struts were present when OLP stenting was per-
formed in normal-appearing arterial segments, whereas
restenosis occurred exclusively in segments with previous high-
grade stenosis.
Chronic total occlusions. Several different mechanisms
might be implicated in ISA after chronic total occlusionPCI. Stent–vessel mismatch, which occurs because the
occluded artery can appear smaller than its actual size due
to chronic hypoperfusion, could be responsible for acute
ISA, whereas injury to the adventitial layer caused by the
guidewire, creation of a false lumen, or subintimal stenting
could contribute to late acquired or persistent ISA. Hong
et al. (16) identiﬁed chronic total occlusion PCI as an in-
dependent predictor of DES ISA. In the same study, the
incidence of ISA in this scenario was 27.5%.
Bifurcations. Coronary artery bifurcations are complex
structures in which stent–vessel interactions are dependent on
several variables, such as stent strut location (i.e., ﬂow divider
or lateral wall) (84), side branch angulation, plaque distri-
bution, or the technique used for stent implantation (i.e., 1 or
2 stents) or post-dilation (i.e., kissing-balloon or separate
main vessel and side branch dilations). The difﬁculty of
achieving adequate stent apposition utilizing 2 stent tech-
niques in coronary artery bifurcations was demonstrated
in vitro by Murasato et al. (85) and Ormiston et al. (86), and
their results were consistent in an in vivo IVUS study that
revealed that more than 60% of the ISA was proximal to
the carina in lesions treated with the “crush” technique (87).
In line with these results, Foin et al. (88) showed, in vitro, that
“crush” stenting led to higher rates of ISA compared with the
Culotte and T with protrusion technique. Tyczynski et al.
(89) used OCT imaging to demonstrate higher rates of ISA
in a side branch compared with non-side branch segments
after bifurcation stenting. Interestingly, no differences be-
tween simple and complex techniques were revealed (89).
Several interventions have been proposed aimed at opti-
mizing stent implantation in bifurcations. Distal cell guide-
wire re-crossing to the side branch led to a reduction of ISA
both in vitro and in vivo (90,91). In the latter, OCT-oriented
guidewire re-crossing to the side branch signiﬁcantly reduced
rates of ISA compared with angiography-oriented pro-
cedures (9.5% vs. 42.3%, respectively; p < 0.0001). Foin
et al. (92) compared the use of a ﬁnal kissing balloon in vitro
with a 2-step (main branch and side branch) ﬁnal balloon
dilation technique in bifurcations. Although the investigators
demonstrated equivalent rates of ISA in the side branch
ostium region for both techniques, they depicted higher
rates of ISA at the proximal stent edge with the kissing
balloon (30.7 26.4% vs. 2.8 9.6% for 2 step, p¼ 0.0016)
(92), which could be reduced by performing an additional
balloon dilation in the proximal stent segment (33.4% vs.
0.6%, respectively, for nonproximal post-dilation and prox-
imal post-dilation; p ¼ 0.02) (93). More recently, Rahman
et al. (94) demonstrated that although kissing-balloon in-
ﬂations led to some amount of proximal main branch stent
asymmetry, the improved stent expansion secondary to that
maneuver was sufﬁcient to adequately appose stent struts in
the majority of cases. Di Mario et al. (95) proposed that
stent optimization in bifurcations could be maximized by
high-resolution intravascular imaging guidance. A large area
of ISA, which was not suspected after angiography-guided
stent optimization with a kissing balloon, was seen by
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13633-dimensional OCT imaging in a case of left main coronary
artery distal bifurcation intervention recently described by
Fujino et al (96). Among 403 patients with IVUS-guided
SES implantation in the left main coronary artery
(including distal bifurcation), 28 presented with acute ISA;
however, no correlations between this pathological phe-
nomenon and adverse cardiovascular events at 2-year clinical
follow-up were established (97). So far, however, no clinical
beneﬁts have been found with the use of routine intravascular
imaging guidance during bifurcation stenting; therefore,
further research in this ﬁeld is mandatory (98).
Vessel tapering. Vessel tapering is frequently observed in
long coronary lesions, which might lead to ISA due to
marked differences in vessel geometry in the same region
of interest. Although multiple post-dilations with different
balloon sizes is the usual strategy used with the aim of
obtaining adequate apposition when stenting distinct
vessel dimensions, aggressive post-dilation with balloons
disproportionately larger than the nominal stent diameter can
lead to stent strut deformation (99) and eventual polymer
damage (100,101). This could negatively affect vascular re-
sponses. Carrozza et al. (102) described increased stent recoil
with larger acute expansion diameters in which excessive
DES overstretching left important gaps between the strut
cells, which could induce suboptimal antirestenotic drug
delivery (103). Importantly, Russo et al. (104) used an animal
to demonstrate that vessel overexpansion might be counter-
productive because it leads to more intense neointimal pro-
liferation. Therefore, reaching equipoise between adequate
(but not excessive) stent expansion and absence of ISA whileFigure 6 STEMI in a Tapered Vessel Treated With Self-Expandable S
(A) An ostial occlusion in the left anterior descending artery (LAD) during ST-segment my
observed in the mid LAD (white arrows). Final result after implantation of 2 STENTYS nitino
in (C). White arrows identiﬁed by letters have their OCT assessments represented with t
whereas distal and proximal references are shown in D and G.avoiding vessel injury is a difﬁcult goal to accomplish in
tapered coronary arteries.Potential Alternatives to Reduce
ISA in Daily Clinical Practice
As previously described, ISA is multifactorial; features directly
related to the index intervention and others associated with
vascular response to stents are implicated in its pathophysi-
ology. Therefore, it is likely that combined, rather than isolated
approaches, are necessary to successfully reduce ISA rates.
Although a clear relationship between ISA and adverse car-
diovascular events is still controversial, interventional cardiol-
ogists must be committed to minimizing acute ISA by
optimizing stent choice and techniques of implantation. Some
novel devices could be helpful in addition to conventional
strategies in this setting. Verheye et al. (105) demonstrated
promising results with the use of self-expandable nitinol stents
(STENTYS, STENTYS SA, Paris, France) in coronary
bifurcations. Interestingly, these devices (either BMS or PES)
have small interconnections that enable easy provisional
stenting and access to the side branch. Progressive stent
expansionwas demonstrated by increasing stent area over time,
which could potentially reduce rates of persistent and late ac-
quired ISA because the stent conforms to vascular remodeling.
Minimal ISA was revealed at 6-month IVUS follow-up. This
same device was tested during primary PCI and demonstrated
an early reduction of ISA compared with balloon-expandable
stents (106). Self-expandable stents could also help reduce
ISA in tapered lesions because the same stent could properlytents
ocardial infarction (STEMI). After ﬂow restoration (B), marked vessel tapering is
l self-expandable stents in the mid and proximal LAD in overlapping fashion is shown
he corresponding letters in E and F; a marked discrepancy in stent areas is shown,
Attizzani et al. JACC Vol. 63, No. 14, 2014
Incomplete Stent Apposition April 15, 2014:1355–67
1364accommodate different vessel dimensions along the lesion
(Fig. 6), thereby avoiding complications (e.g., dissections and
vessel perforation) in smaller segments while allowing optimal
stent apposition in larger segments. Further investigations are
necessary to establish whether self-expandable stents could
reduce adverse clinical outcomes compared with balloon-
expandable stents in all of these clinical settings.
More recently, everolimus-eluting bioresorbable vascular
scaffolds (Absorb, Abbott Vascular, Santa Clara, California)
emerged as a new tool in the armamentarium against coronary
artery disease. These novel devices demonstrated promising
results in randomized studies (107) and are being progressively
incorporated into routine clinical practice in Europe, the
Middle East, and Asia (108–110). Bioresorbable vascular
scaffolds are more conformable than metallic stents (111), and
their struts, including those associated with ISA, are
completely resorbed 2 to 3 years after implantation. This
feature could potentially eliminate concerns related to very
long-term metallic exposure to the coronary circulation in
cases of delayed healing (i.e., ISA and noncoverage) (112,113).
Whether the implantation of these novel devices can reduce
adverse events related to late ISA compared with metallic
stents in real-world populations warrants further investigation.
Another critical step in reducing late ISA, which is not
directly procedure related, is the active search for polymers
and antirestenotic drugs that continue to inhibit neointimal
hyperplasia and induce less toxicity and inﬂammatory re-
actions in the vascular wall, resulting in less positive vascular
remodeling. This “perfect equilibrium” between drug and/or
polymer combinations has been pursued thoroughly by in-
vestigators over recent years in both pre-clinical and clinical
trials with promising results in terms of reducing ISA
(32,37,114–116).Table 2 Summary of Conclusions
ISA is a multifactorial, morphological feature that is affected by
procedure-related elements and by stent-vessel interactions over time.
ISA is more commonly identiﬁed in DES than in BMS.
OCT is superior compared with IVUS in diagnosing ISA.
Although an association between ISA and adverse clinical events is strongly
suggested by histopathology and in vivo studies, highly selected populations
may introduce bias to these ﬁndings; therefore, ISA is the most likely
1 feature among several others that might predispose to ST.
The magnitude of acute ISA may predict its resolution and impact on
vascular healing.
Standardization in data reporting and lesion-level assessment with the evaluation
of clustering and heterogeneity could ultimately lead to a better understanding
of ISA and its impact on clinical outcomes.
Particular clinical scenarios such as acute coronary syndromes, OLP stents,
bifurcations, vessel tapering, and CTO are more prone to exhibit ISA.
Adequate stent sizing, optimal techniques of implantation, and
intravascular imaging guidance can effectively reduce ISA rates.
Novel scaffolds such as self-expandable stents could play a role in reducing ISA
because they can accommodate eventual positive vessel remodeling over time.
Finding antirestenotic drugs and/or polymers that cause less inﬂammation,
and therefore, less positive remodeling, is another important aspect aimed
at reducing ISA.
CTO ¼ chronic total occlusion, DES ¼ drug-eluting stent(s); other abbreviations as in Table 1.Conclusions
The main highlights of this comprehensive review are
summarized in Table 2. ISA is a multifactorial, pathological
feature, and although a clear cause-effect relationship with
ST is still unclear, a body of data suggests that it might
be one of the contributors in the prothrombotic vascular
milieu. Optimal stent sizing and techniques of implantation,
together with the use of new technologies, could minimize
the occurrence of ISA.Acknowledgments
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